In this study, we leveraged a combination of next-generation sequencing and molecular methodologies to provide critical pieces of evidence for a direct role of AR and its clinical inhibitors in regulating the transcriptome of prostate cancer cells by modulating global alternative splicing. This evidence concerns the gene AR and prostate carcinoma.